Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Obesity Medicine
•
Primary Care
How do you decide whether to reinitiate a GLP-1 agonist after a patient has experienced acute pancreatitis while on this therapy?
Answer from: at Community Practice
Will not try it again, given the seriousness of the side effect, and in most cases, there are alternatives.
Sign in or Register to read more
27578
Related Questions
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
Do you recommend the use of GLP1 R agonist therapy in patients with T1DM for weight loss?
How do you counsel patients on the use of compounded weight loss medications?
Should we be more cautious with the use of GLP 1 R agonist therapy in patients with Type 1 diabetes mellitus and obesity given the increased risk of cardiovascular disease with high body weight variability?
How should we approach the recommendation of intermittent fasting for weight loss in patients with pre-existing cardiovascular conditions, given the observed association of increased CV mortality with eating durations of less than 8 hrs?
How would you manage a patient taking a GLP-1 agonist for weight loss who continues to have symptoms (i.e., nausea, vomiting) related to reduced GI motility despite dose adjustments?
What work up do you recommend in post bariatric surgery patients who are slowly gaining back the weight despite no changes in diet?
How do you counsel patients on GLP-1 agonists for weight loss who wish to space out their medication or take a "drug holiday" to temporarily increase their appetite?
What strategies do you employ for adjusting the dosage of levothyroxine in hypothyroid patients who experience significant weight loss or are initiated on GLP-1 receptor agonists?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?